PTC Therapeutics, Inc. Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)
PTC Therapeutics, Inc. (PTCT) reported Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) of $0 for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Notes
us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease · last filed 2020-10-29
- PTC Therapeutics, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2020-09-30 was $0.00.
- PTC Therapeutics, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2020-06-30 was $0.00.
- PTC Therapeutics, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2020-03-31 was $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 3 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 6 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |